These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 7901132)
21. High performance liquid chromatographic assays of the illicit designer drug "Ecstasy", a modified amphetamine, with applications to stability, partitioning and plasma protein binding. Garrett ER; Seyda K; Marroum P Acta Pharm Nord; 1991; 3(1):9-14. PubMed ID: 1677250 [TBL] [Abstract][Full Text] [Related]
22. Chronic paranoid psychosis after misuse of MDMA ("ecstasy"). McGuire P; Fahy T BMJ; 1991 Mar; 302(6778):697. PubMed ID: 1673631 [No Abstract] [Full Text] [Related]
23. Chronic paranoid psychosis after misuse of MDMA. Winstock AR BMJ; 1991 May; 302(6785):1150-1. PubMed ID: 1675133 [No Abstract] [Full Text] [Related]
24. Methyl 3-[3',4'-(methylenedioxy)phenyl]-2-methyl glycidate: an ecstasy precursor seized in Sydney, Australia. Collins M; Heagney A; Cordaro F; Odgers D; Tarrant G; Stewart S J Forensic Sci; 2007 Jul; 52(4):898-903. PubMed ID: 17553085 [TBL] [Abstract][Full Text] [Related]
25. Determination of MDMA, MDA, MDEA and MBDB in oral fluid using high performance liquid chromatography with native fluorescence detection. Concheiro M; de Castro A; Quintela O; López-Rivadulla M; Cruz A Forensic Sci Int; 2005 Jun; 150(2-3):221-6. PubMed ID: 15944063 [TBL] [Abstract][Full Text] [Related]
26. Screening of synthetic PDE-5 inhibitors and their analogues as adulterants: analytical techniques and challenges. Patel DN; Li L; Kee CL; Ge X; Low MY; Koh HL J Pharm Biomed Anal; 2014 Jan; 87():176-90. PubMed ID: 23721687 [TBL] [Abstract][Full Text] [Related]
27. [Contaminants in illegal amphetamine. Basic contaminants in drug market 3,4-(methylenedioxy)methylamphetamine]. Verweij AM Arch Kriminol; 1991; 188(5-6):154-8. PubMed ID: 1686826 [TBL] [Abstract][Full Text] [Related]
28. Determination of MDMA, MDEA and MDA in urine by high performance liquid chromatography with fluorescence detection. da Costa JL; da Matta Chasin AA J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Nov; 811(1):41-5. PubMed ID: 15458720 [TBL] [Abstract][Full Text] [Related]
29. Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations. Ricaurte GA; Finnegan KT; Irwin I; Langston JW Ann N Y Acad Sci; 1990; 600():699-708; discussion 708-10. PubMed ID: 1701292 [No Abstract] [Full Text] [Related]
30. Stability study of the designer drugs "MDA, MDMA and MDEA" in water, serum, whole blood, and urine under various storage temperatures. Clauwaert KM; Van Bocxlaer JF; De Leenheer AP Forensic Sci Int; 2001 Dec; 124(1):36-42. PubMed ID: 11741758 [TBL] [Abstract][Full Text] [Related]
31. Increasing use of "Ecstasy" (MDMA) and other hallucinogens on a college campus. Cuomo MJ; Dyment PG; Gammino VM J Am Coll Health; 1994 May; 42(6):271-4. PubMed ID: 7913938 [TBL] [Abstract][Full Text] [Related]
32. Application of ORAL.screen saliva drug test for the screening of methamphetamine, MDMA, and MDEA incorporated in hair. Miki A; Katagi M; Shima N; Tsuchihashi H J Anal Toxicol; 2004 Mar; 28(2):132-4. PubMed ID: 15068568 [TBL] [Abstract][Full Text] [Related]
33. Ion trap mass spectrometry for the characterization of N-methyl-1- (3,4-methylene-dioxyphenyl)-2-butanamine and N-ethyl-3,4- methylenedioxyamphetamine, two widely distributed street drugs. Garofano L; Santoro M; Patri P; Guidugli F; Bollani T; Favretto D; Traldi P Rapid Commun Mass Spectrom; 1998; 12(12):779-82. PubMed ID: 9650303 [TBL] [Abstract][Full Text] [Related]
34. Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for enantioselective measurement of the designer drugs MDEA, MDMA, and MDA and its application to samples from a controlled study with MDMA. Peters FT; Samyn N; Lamers CT; Riedel WJ; Kraemer T; de Boeck G; Maurer HH Clin Chem; 2005 Oct; 51(10):1811-22. PubMed ID: 16099938 [TBL] [Abstract][Full Text] [Related]
35. 3,4-Methylenedioxymethamphetamine (MDMA) and other amphetamine derivatives. Bost RO J Forensic Sci; 1988 Mar; 33(2):576-87. PubMed ID: 2897421 [TBL] [Abstract][Full Text] [Related]
36. Identification of five substituted phenethylamine derivatives 5-MAPDB, 5-AEDB, MDMA methylene homolog, 6-Br-MDMA, and 5-APB-NBOMe. Liu C; Jia W; Qian Z; Li T; Hua Z Drug Test Anal; 2017 Feb; 9(2):199-207. PubMed ID: 26856255 [TBL] [Abstract][Full Text] [Related]
37. Second thoughts on 3,4-methylenedioxymethamphetamine (MDMA) neurotoxicity. Grob C; Bravo G; Walsh R Arch Gen Psychiatry; 1990 Mar; 47(3):288-9. PubMed ID: 1968330 [No Abstract] [Full Text] [Related]
38. Spectrophotometric and liquid chromatographic identification of 3,4-methylenedioxyphenylisopropylamine and its N-methyl and N-ethyl homologs. Noggle FT; DeRuiter J; Long MJ J Assoc Off Anal Chem; 1986; 69(4):681-6. PubMed ID: 2875058 [TBL] [Abstract][Full Text] [Related]
39. [Mass spectrometry data of some metabolites of the amphetamine derivatives 3,4-(methylenedioxy) amphetamine (MDA) and 3,4-methylenedioxy)methylamphetamine (MDMA)]. Verweij AM Arch Kriminol; 1996; 197(1-2):27-30. PubMed ID: 8851250 [TBL] [Abstract][Full Text] [Related]
40. The MDMA-neurotoxicity controversy: implications for clinical research with novel psychoactive drugs. Grob CS; Bravo GL; Walsh RN; Liester MB J Nerv Ment Dis; 1992 Jun; 180(6):355-6. PubMed ID: 1350614 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]